Pfizer In. said on March 23 the company’s experimental treatment for an inflammatory bowel disease, acquired during 2021 as part of a $6.7 billion deal for Arena Pharmaceuticals, succeeded in a late-stage trial.
Gilead Sciences and Google/Alphabet’ Verily Life Sciences teamed up to focus on three inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and lupus-related diseases.
Nestle is investing 20 million euros in a joint venture with Enterome SA to develop microbiome-based diagnostics for inflammatory bowel and liver diseases.
Irish drugmaker Shire Plc said it would buy the rights to an experimental bowel drug from Pfizer Inc to bolster its pipeline of gastrointestinal treatments.
November 5, 2015By Mark Terry, BioSpace.com Breaking News Staff After Cambridge, Mass.-based Biogen, Inc. (BIIB) presented its research and development ambitions on Tuesday, analysts have started examining the company’s strategy. On Oct. 21, 2015, Biogen released its third-quarter financials which included $2.8 billion in revenues, an 11 percent increase compared to the third quarter […]